UCLH-6630 - LECANEMAB HOMECARE SERVICE

The service requirements for the direct supply and administration of Lecanemab (Leqembi) in a patient's home, via a homecare delivery service. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoE ε 4) heterozygotes or non-carriers. The service is being offered by UCLH private Healthcare and will be for private patients only. The requirement is for a private homecare provider situated in the UK to provide this service.